Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
In April 2024, product shipped and first patients received Rezdiffra, the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) On March 5, 2024, announced validation of European Medicines Agency marketing application for resmetirom Raised $690 million in gross proceeds from upsized public offering and full over-allotment exercise Reports cash, cash equivalents and marketable securities of $1.1 billion at March 31, 2024 Company to host conference call today, May 7, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Madrigal is the first company to deliver an approved therapy for patients with NASH, which we believe wil
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Paulson & Co's top buy and sells in Q1 [Seeking Alpha]Seeking Alpha
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at B. Riley from $270.00 to $200.00. They now have a "neutral" rating on the stock.MarketBeat
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Citigroup Inc. from $389.00 to $382.00. They now have a "buy" rating on the stock.MarketBeat
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at HC Wainwright from $425.00 to $390.00. They now have a "buy" rating on the stock.MarketBeat
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at JMP Securities from $397.00 to $381.00. They now have a "market outperform" rating on the stock.MarketBeat